NCT06388642View on ClinicalTrials.gov

Pharmacokinetics of Afamelanotide in EPP Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

October 28, 2024

Study Completion Date

January 20, 2025

Conditions
Erythropoietic Protoporphyria
Interventions
DRUG

Afamelanotide 16mg implant

afamelanotide 16mg implant will be administered to each patient during the study.

Trial Locations (2)

Unknown

CLINUVEL Site, Leuven

CLINUVEL Site, Rotterdam

All Listed Sponsors
lead

Clinuvel Europe Limited

INDUSTRY